Biomea Fusion, Inc. (“Biomea”) (nasdaq: bmea), a clinical-stage diabetes and obesity company, announced today that it has commended an underwritten public offering of shares of being common stock and accompanyinging to purcha themes of its) and esoge in larrants in lares and its in larrants in liares in liabites in liares in liares in liares in liares in liabites in liares in liab its in liares in liefs, and ity in liasts in liefs, and it. Or Common Stock to Certain Investors, Pre-Funded Warrants to Purchase Shares of its Common Stock and associated Warrants to buy shares of its ordinary shares (or pre-financed warrants instead). In addition, BIOMEA is planning to give the insurers an option of 30 days to buy up to an additional fifteen percent (15%) of the shares of ordinary shares and warrants to buy shares of ordinary shares in the proposed offer. All shares, pre -financed warrants and associated ordinary stock payments that are sold in the proposed offer must be sold by Biomea.
The proposed supply is subject to market and other conditions, and there can be no certainty about whether the proposed offer can be completed, or with regard to the actual size or conditions of the proposed offer.
Jefferies is the only book running manager for the proposed offer.
The shares of ordinary shares, pre-financed warrants, ordinary shares and shares of ordinary shares issued in the exercise of the pre-financed warrants and ordinary stock complies are offered by Biomea based on an effective plank registration overview on form S-3 (file no. 333-29222), (Sect “) on the US Securities and Exchange Commission (sect”) on 5, August 2025 and indicated in August 2025 and indicated in August 2025 and indicated August 2025 and indicated in August 2025 and indicated. A preliminary prospectus supplement and accompanying prospectus with regard to and describing the conditions of the proposed offer will be submitted to the SEC and can also be obtained if available, from: Jefferies LLC by post at Attn: Equity Syndicate Prospectus Department, 520 Madison Avenue, New York, New York) 821-7388, or by e-mail at telephone on (877) prospectus_department@jefferies.com or by gaining access to the website of the SEC on www.sec.gov.
This press release is not an offer to sell or the request for an offer to buy these effects, nor will there be a sale of these effects in a state or jurisdiction in which such an offer, requests or sale would be prior to registration or qualification under the securities laws of such a state or jurisdiction.
About Biomea merger
Biomea merger is a clinical stage Diabetes and obesity medicine company aimed at the development of oral therapies for small molecules, ICOVAMENIB and BMF-650, for diabetes and obesity. These programs are aimed at metabolic disorders, a global health challenge that affects almost half of the Americans and a fifth of the world’s population. Biomea’s mission is to provide transformative treatments that restore health for patients who live with diabetes, obesity and related disorders. We strive for healing.
Foresighting statements
This press release contains future -oriented statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, statements about the beliefs and expectations of Biomea with regard to the proposed offer; Uncertainties with regard to market conditions and statements with regard to timing, size and expected yields of the proposed supply and the research, development and regulations plans of Biomea, the progress of current and upcoming clinical investigations and the timing of such events. The words “May”, “Wil”, “would” “” “” “” “” “” “” “” “” “Plan”, “anticipation”, “anticipating”, intensive “,” faith “,” estimate “,” predicting “,” project “” project “” Potential “,” goal “and comparable expressions to identifying predetermined explanations, although not all, although not all, although not all, although not all, although not to identify, although not all statements, although not all, although
Any Forward-look statements in this press release are based on management’s current expectations and beliefs of Future Events and are subject to a number of risks, uncertainties and Important Factors That May Cause Actual Evessed or Imthy Latery-Lay-Layer-Lay-Lay-Lay-Layer-L Contained in this press release, Including, Without Limitation, Uncertainties Related to Completion of the Propose Public Offering on the Anticipated Terms, OR at All, Market Conditions and Statements Regarding the Timing, Size and Acquisition of the Biesty of the Property, The Subsidy of the Property, the Subsidy of the Property, The Subsidy of the Property, The Property, The Property, The Property The Property, The Term Subsidy, The Term Subsidy, The Term Subsidy, The Property Support, The Term Subsidy, The Term Subsidy, The Term Subsidy, The Term Subsidy, The Term Subsidy, The Insurance and The Subservated Offer, The Adsiden Terms Intended Offer, The Adsidig, The Intended Offer, The Term Studies and The Insurance Support Offer. complete the proposed offer. These and other risks and uncertainties are described in Greater Detail in the section entitled “Risk Factors” in biomea’s most recent annual report on form 10-k filed on march 31, 2025 and sub-consisting quarterly reports on form 10-q filed, as well as well, as well as well, as well as well as well as well as well. Other Important Factors in Biomea’s Other Filings with the SEC, Including Those Contained or Incorporated by Reference in the Preliminary Prospectus Supplement and accompanying prospectus with regard to the proposed offer that must be submitted to the SEC. All future -oriented statements in this press release represent the views of Biomea only from the date of this and may not be trusted as its display on a subsequent date. Biomea explicitly accepts any obligation to update future -oriented statements, except as legally required.
Contact:
Mechiere Jennifer Weiss
Sr. Director, Investor Relations and Corporate Development
Ir@biomeafusion.com
#Biomea #Fusion #announces #proposed #public #offer #securities